Market Trends of Polyclonal Antibodies Industry
Secondary Antibody Segment is Expected to Dominate the Polyclonal Antibodies Market Over the Forecast Period
A secondary antibody recognizes an antibody or antibody domain from a different species. They bind primary antibodies in various experimental schemes and have immense applications in diagnostics therapeutics for infectious diseases caused by bacteria, viruses, protozoa and cancer, and metabolic and hormonal disorders. The segment is expected to hold a significant market share during the forecast period, owing to the rising investment in secondary antibody research and increased antibody-based product launches. For instance, in 2022, Jackson ImmunoResearch Laboratories launched their latest product, AffiniPure-VHH, and it will be used for high-resolution immunohistochemistry and immunofluorescence. Additionally, biopharmaceutical corporations are funding the development of novel antibody research that has the potential to benefit humanity by treating diseases. For instance, in March 2023, Pfizer, a leading biopharmaceutical industry, and Seagen, a biotechnology company, announced that they have entered into a definitive merger agreement under which Pfizer will acquire Seagen. They will seek to accelerate the next generation of cancer by bringing power to antibody-drug conjugate and other innovative antibody platforms that directly engage the immune system to destroy tumors.
Furthermore, factors such as rising research and development leading to product approvals and launches are also fuelling the segment growth. For instance, In October 2023, a US-based biotechnology company, Proteintec, a global leader in antibodies, launched Multi-rAb Recombinant Secondary Antibodies, the newest generation of secondary antibodies designed to deliver unparalleled specificity and reproducibility in widely used immunoassays. Hence, these all have contributed to the significant growth of the market.
North America is Expected to Dominate the Polyclonal Antibodies Market over the Forecast Period
North America is expected to hold a significant share of antibody production owing to the high prevalence of cancer in the region, the strong presence of favorable healthcare infrastructure, and innovations and product launches by market players in the area.
The American Cancer Society Cancer Statistics 2022 states that there will likely be 1.92 million new cases of cancer diagnosed in the country. Leukemia is expected to have 60,650 new cases, lymphoma to have 89,010 new cases, and breast cancer to have 290,560 new cases out of all cancer cases in the United States. The rise in the approval of antibodies for the treatment of cancer and other diseases will contribute to the market growth in this region. For instance, in April 2023, a US-based Biotechnology named Rallybio announced clinical proof of concept results for RLYB211, a polyclonal antibody for the prevention of fetal and neonatal alloimmune thrombocytopenia.
Moreover, the antibody production expansion by key regional players is also fuelling market growth. For instance, in October 2022, SAB Biotherapeutic, a US-based clinical-stage Biopharmaceutical company, announced that the company had entered an exclusive manufacturing services contract with Emergent BioSolutions Inc., a biopharmaceutical company based in Canada. Emergent will develop contracts and manufacture CDMO services to produce SAB’s fully human polyclonal antibody products.
Hence, factors such as increased demand for biological medicine, which drives antibody production, as well as the development of revolutionary technologies and product launches, will drive profitable growth in the region throughout the projection period.
